section name header

Evidence summaries

Nsaids for Axial Spondyloarthritis

Both traditional and COX-2 NSAIDs are more efficacious than placebo for treating axial spondyloarthritis. Level of evidence: "A"

Summary

A Cochrane review [Abstract] 1 of the effect of non-steroidal anti-inflammatory drugs (NSAIDs) for people with axial spondyloarthritis (axSpA) included 39 studies (35 RCTs, 2 quasi-RCTs and 2 cohort studies) of which 29 RCTs and two quasi-RCTs (n = 4 356) were included in quantitative analyses.

Traditional NSAIDs (table T1) and COX-2 NSAIDs (table T2) were more efficacious than placebo in the outcomes of pain, disease activity and functional capacity, and did not lead to more withdrawals due to adverse events (AEs), or increase in the number of serious AEs. When looking at the number of adverse events per organ system, there were more gastro-intestinal adverse events (RR 1.92, 95% CI 1.41 to 2.61; 5 studies, n=1 289) and fewer neurological adverse events (including headache and dizziness) (RR 0.44, 95% CI 0.24 to 0.82; 4 studies, n=1 144) in patients taking traditional NSAIDs compared to placebo. In patients taking COX-2 NSAIDs, there were more gastro-intestinal adverse events compared to placebo (RR 1.80, 95% CI 1.22 to 2.67; 3 studies, n=669), and in the other organ systems that were assessed (respiratory, neurological and dermatological) there was no difference in the number of adverse events.

Traditional NSAIDs compared with placebo

OutcomeFollow-upRelative effect(95% CI)Assumed risk - placeboCorresponding risk - traditional NSAID (95% CI)Participants (studies)
BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index
Pain on VASScale from 0 to 100 mm (higher is worse)2 to 6 weeks The mean pain score in the control group was61 pointsThe mean pain scores in the intervention groups was 16.5 points lower (12.2 to 20.8 lower)850 (4 studies)
BASDAIScale from 0 to 100 (higher is worse)6 weeks The mean BASDAI in the control group was54.7 pointsThe mean BASDAI in the intervention group was17.5 points lower (11.8 to 23.1 lower)190 (1 study)
BASFIScale from 0 to 100 (higher is worse)6 weeks The mean BASFI in the control groups was50.0 pointsThe mean BASFI in the intervention groups was9.1 points lower (5.1 to 13.0 lower)356 (2 studies)
Withdrawals due to adverse events2 to 12 weeksRR 0.75 (0.46 to 1.21)52 per 100039 per 1000 (24 to 63)1 165 (5 studies)
Number of serious adverse events6 to 12 weeksRR 1.69 (0.36 to 7.97)2 per 10003 per 1000(1 to 16)671 (3 studies)

There were no significant differences in benefits or harms between traditional NSAID and COX-2 NSAID classes. Single studies suggested NSAIDs may be effective in retarding radiographic progression of the spine in axSpA, especially in certain subgroups of patients, e.g. patients with high CRP, and that this may be best achieved by continuous rather than on-demand use of NSAIDs.

COX-2 NSAIDs compared with placebo

OutcomeFollow-upRelative effect(95% CI)Assumed risk - placeboCorresponding risk - COX-2 NSAID (95% CI)Participants (studies)
BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index
Pain on VASScale from 0 to 100 mm (higher is worse)6 weeks The mean pain scores across control groups was64 pointsThe mean pain scores in the intervention groups was 21.7 points lower (7.4 to 35.9 lower)349 (2 studies)
BASDAIScale from 0 to 100 (higher is worse)6 weeks The mean BASDAI in the control group was54.7 pointsThe mean BASDAI in the intervention group was22 points lower (16.6 to 27.4 lower)193 (1 study)
BASFIScale from 0 to 100 (higher is worse)6 weeks The mean BASFI in the control groups was50.0 pointsThe mean BASFI in the intervention groups was13.4 points lower (9.5 to 17.4 lower)349 (2 studies)
Withdrawals due to adverse events6 to 12 weeksRR 2.14 (0.36 to 12.56)11 per 100024 per 1000(4 to 142)669 (3 studies)
Number of serious adverse events6 to 12 weeksRR 0.92 (0.14 to 6.21)2 per 10002 per 1000 (0 to 13)669 (3 studies)

Clinical comments

Note

Date of latest search:

References

  • Kroon FP, van der Burg LR, Ramiro S et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev 2015;(7):CD010952. [PubMed]

Primary/Secondary Keywords